Oxford BioMedica (LSE:OXB) Net Margin %: -3.94% (As of Dec. 2025)


LSE:OXB Oxford BioMedica PLC LSE:OXB
68 GF Score
Price £6.14
GF Value £5.35
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Net Margin %?

Oxford BioMedica LSE:OXB +2.33% 68 Net Margin % is -3.94% as of Dec. 2025. GuruFocus rates LSE:OXB with a GF Score™ of 68/100 and a GF Value™ of £5.35 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 947 Biotechnology companies, Oxford BioMedica ranks better than 63.46% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Oxford BioMedica's Net Income for the six months ended in Dec. 2025 was £-3.8 Mil. Oxford BioMedica's Revenue for the six months ended in Dec. 2025 was £95.5 Mil. Therefore, Oxford BioMedica's net margin for the quarter that ended in Dec. 2025 was -3.94%.

The historical rank and industry rank for Oxford BioMedica's Net Margin % or its related term are showing as below:

LSE:OXB' s Net Margin % Range Over the Past 10 Years
Min: -175.89   Med: -24.54   Max: 13.31
Current: -17.86

LSE:OXB's Net Margin % is ranked better than
63.46% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs LSE:OXB: -17.86

Oxford BioMedica  (LSE:OXB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Oxford BioMedica Net Margin % Related Terms

Oxford BioMedica Net Margin % Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Net Margin % Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.31 -27.97 -175.89 -33.53 -17.85

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -235.67 -63.94 -13.73 -36.00 -3.94

LSE:OXB vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Oxford BioMedica's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Net Margin % distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Net Margin % falls into.


LSE:OXB
68GF Score
Oxford BioMedica PLC LSE:OXB
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Oxford BioMedica's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-30.128/168.741
=-17.85 %

Oxford BioMedica's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.768/95.518
=-3.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -3.94% mean?
Oxford BioMedica (LSE:OXB) has a Net Margin % of -3.94% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #346 out of 947 companies in the Biotechnology industry, placing it in the top 36.5%.
Is Oxford BioMedica's Net Margin % too high?
Oxford BioMedica's current Net Margin % is -3.94%. Based on the distribution chart, Oxford BioMedica ranks #346 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #346 out of 947 companies for Net Margin %. This puts Oxford BioMedica in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current Net Margin % is -3.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.35, compared to a current price of £6.14 — trading 14.8% above its estimated fair value. The current Net Margin % is -3.94%. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current Net Margin % is -3.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of £6.14 is trading 14.8% above its estimated GF Value™ of £5.35. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for LSE:OXB:

  • Net Margin %: -3.94%
  • GF Value™: £5.35 vs. price of £6.14 (14.8% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBDF:USAOXBl:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score

Get the complete analysis for LSE:OXB

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£6.14
Price
£5.35
GF Value